Your browser doesn't support javascript.
loading
Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.
Hassan, Md Sazzad; Awasthi, Niranjan; Li, Jun; Williams, Fiona; Schwarz, Margaret A; Schwarz, Roderich E; von Holzen, Urs.
Afiliação
  • Hassan MS; Department of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617. Electronic address: hassansa@iu.edu.
  • Awasthi N; Department of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617.
  • Li J; Department of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, IN 46556.
  • Williams F; Department of Biological Sciences, University of Notre Dame, IN 46556.
  • Schwarz MA; Harper Cancer Research Institute, South Bend, IN 46617; Department of Biological Sciences, University of Notre Dame, IN 46556; Department of Pediatrics, Indiana University School of Medicine, South Bend, IN 46617.
  • Schwarz RE; Department of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617; Goshen Center for Cancer Care, Goshen, Goshen, IN 46526.
  • von Holzen U; Department of Surgery, Indiana University School of Medicine, South Bend, IN 46617; Harper Cancer Research Institute, South Bend, IN 46617; Goshen Center for Cancer Care, Goshen, Goshen, IN 46526; University of Basel, Basel, Switzerland.
Transl Oncol ; 11(2): 426-435, 2018 Apr.
Article em En | MEDLINE | ID: mdl-29475139
Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel albumin-stabilized, cremophor-free and water soluble nanoparticle formulation of paclitaxel, and the potential role of nab-paclitaxel has not been tested yet in experimental EAC. Here we tested the antiproliferative and antitumor efficacy with survival advantage of nab-paclitaxel as monotherapy and in combinations in in-vitro, and in murine subcutaneous xenograft and peritoneal metastatic survival models of human EAC. Nab-paclitaxel significantly inhibited in-vitro cell proliferation with higher in-vivo antitumour efficacy and survival benefit compared to paclitaxel or carboplatin treatments both in mono- and combination therapies. Nab-paclitaxel treatment increased expression of mitotic-spindle associated phospho-stathmin, decreased expression of proliferative markers and enhanced apoptosis. This study demonstrates that nab-paclitaxel had stronger antiproliferative and antitumor activity in experimental EAC than the current standard chemotherapeutic agents which supports the rationale for its clinical use in EAC.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Transl Oncol Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Transl Oncol Ano de publicação: 2018 Tipo de documento: Article